RSS

Autolus

Clinical-stage biopharmaceutical company, Autolus, and provider of products and services for biomedical research and cellular therapy, Miltenyi Biotec, have signed a strategic long-term supply agreement. more

News

UK-based biopharmaceutical company, Autolus, has announced its participation in the Northern Alliance Advanced Therapies Treatment Centre (NAATTC) and support of the Innovate Manchester Advanced Therapy Centre Hub (iMATCH) consortium. more

News

Clinical-stage biopharmaceutical company, Autolus, has announced the publication of pre-clinical data of a novel, dual-targeted, proliferating-inducing ligand (APRIL) chimeric antigen receptor (CAR) for the treatment of multiple myeloma. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Clinical-stage biopharmaceutical company, Autolus, has presented data for its pan-checkpoint blocking technology at the American Society of Hematology (ASH) annual meeting in Atlanta. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Clinical-stage biopharmaceutical company, Autolus has announced the publication of an article detailing a unique targeting strategy for the treatment of patients with T-cell lymphomas in Nature Medicine. more

News

Clinical-stage biopharmaceutical company, Autolus, has secured $80 million in series C financing, which it will use to establish clinical proof of concept for three novel haematological cancer programmes. more

News

Clinical-stage, biopharmaceutical start-up company, Autolus, steps into the chimeric antigen receptor (CAR)-T cell therapy fray with three new studies looking at the treatment of various cancers. more

News